Public Health Initiatives

 pale yellow background with taupe lines on left side

Advancing Public Health Through Access and Evidence

Knoa Pharma is committed to addressing critical public health challenges related to opioid use disorder and opioid overdose.

Our Public Health Initiatives are evidence-based efforts focused on expanding access to lifesaving overdose reversal tools and medication for opioid use disorder. These initiatives operate under a not-for-profit model designed to make treatments available at or below the cost of production.

Areas of Focus

Expanding Access to Evidence-Based Treatment

Medications for opioid use disorder (MOUD) remain underutilized, particularly in correctional settings and during transitions back to the community.1,2,3

Knoa Pharma’s public health efforts focus on reducing barriers to access and supporting continuity of care for populations at increased risk.

Enhancing Community Overdose Prevention and Response

The ongoing and evolving overdose crisis, driven largely by potent synthetic opioids,4 highlights the need for harm reduction strategies and multiple clinically appropriate treatment options.

Knoa Pharma supports initiatives that strengthen overdose preparedness and response across emergency, prehospital, and healthcare settings.

Deepening Learning and Collaboration to Address the Evolving Opioid Crisis

Real-world data and outcomes research are essential to understanding the evolving opioid crisis, how overdose interventions and treatments for opioid use disorder are used in practice, and how they influence patient outcomes, healthcare resource utilization, and transitions to ongoing care.

To advance this work, Knoa Pharma invests in research partnerships and observational studies designed to address critical evidence gaps related to opioid overdose treatment. These efforts support responsible, data-driven public health decision-making and align with expert recommendations for continued evidence development.

Opioid Overdose Reversal Publications

To learn more about Knoa Pharma’s published research on medicines for opioid overdose reversal, click here.

References:

  1. Berk J, South AM, Martin M, James ME, Miller C, Haber L, Rich J. Medication for opioid use disorder service delivery in carceral facilities: update and summary report. Health Justice. 2025 Feb 1;13(1):8. doi: 10.1186/s40352-025-00317-9. PMID: 39891797; PMCID: PMC11786385.
  2. Friedmann PD, Wilson D, Stopka TJ, Bernson D, Pivovarova E, Ferguson W, Hoskinson RA Jr, Rottapel RE, Bovell-Ammon B, Gaba A, Morgan JR, Senst T, Hayes E, Evans EA; Mass JCOIN Research Hub. Medications for Opioid Use Disorder in County Jails – Outcomes after Release. N Engl J Med. 2025 Sep 11;393(10):994-1003. doi: 10.1056/NEJMsa2415987. PMID: 40929634; PMCID: PMC12646036.
  3. Substance Abuse and Mental Health Services Administration: Guidelines for Implementing Medication for Opioid Use Disorder Treatment in State Prisons. Rockville, MD: Center for Substance Abuse Treatment. Substance Abuse and Mental Health Services Administration, 2025.
  4. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2026. DOI: https://dx.doi.org/10.15620/cdc/20250305008
×